Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Evidence for atypical nest overwintering by hatchling lizards, Heloderma suspectum.

DeNardo DF, Moeller KT, Seward M, Repp R.

Proc Biol Sci. 2018 May 30;285(1879). pii: 20180632. doi: 10.1098/rspb.2018.0632.

PMID:
29794051
2.

Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment.

Heidkamp GF, Sander J, Lehmann CHK, Heger L, Eissing N, Baranska A, Lühr JJ, Hoffmann A, Reimer KC, Lux A, Söder S, Hartmann A, Zenk J, Ulas T, McGovern N, Alexiou C, Spriewald B, Mackensen A, Schuler G, Schauf B, Forster A, Repp R, Fasching PA, Purbojo A, Cesnjevar R, Ullrich E, Ginhoux F, Schlitzer A, Nimmerjahn F, Schultze JL, Dudziak D.

Sci Immunol. 2016 Dec 16;1(6). pii: eaai7677. doi: 10.1126/sciimmunol.aai7677. Epub 2016 Dec 16.

PMID:
28783692
3.

Dental status does not predict infection during stem cell transplantation: a single-center survey.

Guenther A, Losch E, Schiessl M, Schrauder A, Humpe A, Repp R, Nitsche T, Wiltfang J, Gramatzki M.

Bone Marrow Transplant. 2017 Jul;52(7):1041-1043. doi: 10.1038/bmt.2017.76. Epub 2017 May 8. No abstract available.

PMID:
28481351
4.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

5.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
6.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

PMID:
26522083
7.

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.

Staudinger M, Glorius P, Burger R, Kellner C, Klausz K, Günther A, Repp R, Klapper W, Gramatzki M, Peipp M.

Blood Cancer J. 2014 Jun 13;4:e219. doi: 10.1038/bcj.2014.38.

8.

A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity.

Lux A, Seeling M, Baerenwaldt A, Lehmann B, Schwab I, Repp R, Meidenbauer N, Mackensen A, Hartmann A, Heidkamp G, Dudziak D, Nimmerjahn F.

Cell Rep. 2014 Apr 10;7(1):236-48. doi: 10.1016/j.celrep.2014.02.041. Epub 2014 Mar 27.

9.

Mating systems, reproductive success, and sexual selection in secretive species: a case study of the western diamond-backed rattlesnake, Crotalus atrox.

Clark RW, Schuett GW, Repp RA, Amarello M, Smith CF, Herrmann HW.

PLoS One. 2014 Mar 5;9(3):e90616. doi: 10.1371/journal.pone.0090616. eCollection 2014.

10.

Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.

Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, Nickelsen M, Schrauder A, Schrappe M, Kneba M, Gramatzki M.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1632-7. doi: 10.1016/j.bbmt.2013.07.003. Epub 2013 Jul 11.

11.

A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy.

Schimke LF, Rieber N, Rylaarsdam S, Cabral-Marques O, Hubbard N, Puel A, Kallmann L, Sombke SA, Notheis G, Schwarz HP, Kammer B, Hökfelt T, Repp R, Picard C, Casanova JL, Belohradsky BH, Albert MH, Ochs HD, Renner ED, Torgerson TR.

J Clin Immunol. 2013 Aug;33(6):1088-99. doi: 10.1007/s10875-013-9906-1. Epub 2013 May 25.

PMID:
23708964
12.

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.

Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2013 Jul;27(7):1595-8. doi: 10.1038/leu.2012.373. Epub 2013 Jan 1. No abstract available.

PMID:
23277329
13.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.

J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.

14.

Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.

Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M.

Ann Hematol. 2012 Nov;91(11):1765-72. doi: 10.1007/s00277-012-1534-y. Epub 2012 Aug 29. Review.

PMID:
22926531
15.

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.

Mohseni Nodehi S, Repp R, Kellner C, Bräutigam J, Staudinger M, Schub N, Peipp M, Gramatzki M, Humpe A.

PLoS One. 2012;7(8):e42426. doi: 10.1371/journal.pone.0042426. Epub 2012 Aug 3.

16.

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.

Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4.

PMID:
22660187
17.

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2012 Apr;26(4):830-4. doi: 10.1038/leu.2011.288. Epub 2011 Oct 18. No abstract available.

PMID:
22005785
18.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
19.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J.

Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9.

20.

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA.

Blood. 2010 Oct 21;116(16):3004-12. doi: 10.1182/blood-2010-01-265280. Epub 2010 Jul 8.

21.

Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.

Schub N, Günther A, Schrauder A, Claviez A, Ehlert C, Gramatzki M, Repp R.

Bone Marrow Transplant. 2011 Jan;46(1):143-7. doi: 10.1038/bmt.2010.68. Epub 2010 Mar 29.

PMID:
20348971
22.

A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.

Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B.

J Immunol. 2010 Feb 1;184(3):1210-7. doi: 10.4049/jimmunol.0902033. Epub 2009 Dec 30.

23.

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.

Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268.

24.

Massive swelling of the cervical region: an uncommon manifestation of B cell chronic lymphocytic leukemia.

Becker ST, Wiltfang J, Klapper W, Repp R, Sinis N, Warnke PH.

Oral Maxillofac Surg. 2008 Dec;12(4):205-8. doi: 10.1007/s10006-008-0128-2.

PMID:
18688662
25.

Successful autologous hematopoietic progenitor cell transplantation in a patient with an isoantibody against CD36 (glycoprotein IV, Naka).

Flesch B, Miller J, Repp R, Ott S, Gahn B, Schub N, Gramatzki M, Humpe A.

Bone Marrow Transplant. 2008 Oct;42(7):489-91. doi: 10.1038/bmt.2008.190. Epub 2008 Jul 14. No abstract available.

PMID:
18622422
26.

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T.

Blood. 2008 Sep 15;112(6):2390-9. doi: 10.1182/blood-2008-03-144600. Epub 2008 Jun 19.

27.

Cup-like acute myeloid leukemia: new disease or artificial phenomenon?

Kroschinsky FP, Schäkel U, Fischer R, Mohr B, Oelschlaegel U, Repp R, Schaich M, Soucek S, Baretton G, Ehninger G, Thiede C; DSIL (Deutsche Studieninitiative Leukämie) Study Group.

Haematologica. 2008 Feb;93(2):283-6. doi: 10.3324/haematol.11669. Epub 2008 Jan 26.

28.

Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.

Gahn B, Schub N, Repp R, Gramatzki M.

Eur J Med Res. 2007 Aug 16;12(8):337-40.

PMID:
17933709
29.
30.

A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.

Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, Gramatzki M, Valerius T.

Leuk Lymphoma. 2006 Oct;47(10):2147-54.

PMID:
17071489
31.

Genotype-dependent activation or repression of HBV enhancer II by transcription factor COUP-TF1.

Fischer SF, Schmidt K, Fiedler N, Glebe D, Schüttler C, Sun J, Gerlich WH, Repp R, Schaefer S.

World J Gastroenterol. 2006 Oct 7;12(37):6054-8.

32.

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG).

Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31.

33.

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.

Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.

J Clin Oncol. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24.

PMID:
16864854
34.

Winter profile of plasma sex steroid levels in free-living male western diamond-backed rattlesnakes, Crotalus atrox (Serpentes: Viperidae).

Schuett GW, Repp RA, Taylor EN, DeNardo DF, Earley RL, Van Kirk EA, Murdoch WJ.

Gen Comp Endocrinol. 2006 Oct;149(1):72-80. Epub 2006 Jul 7.

PMID:
16828091
35.

Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents.

Metzler M, Luedecke DK, Saeger W, Grueters A, Haberl H, Kiess W, Repp R, Rascher W, Doetsch J.

Cancer Genet Cytogenet. 2006 Apr 15;166(2):146-51.

PMID:
16631471
36.

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.

Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, Birkmann J, Oduncu F, Emmerich B, Fey GH.

Br J Haematol. 2006 Apr;133(2):141-51.

PMID:
16611304
37.

Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma.

Hoffmann C, Repp R, Schoch R, Gahn B, Schub N, Beck C, Humpe A, Kneba M, Horst HA, Schmitz N, Gramatzki M.

Eur J Med Res. 2006 Feb 21;11(2):73-6.

PMID:
16504964
38.

Multiple bone lesions of systemic multifocal fibrosclerosis.

Blank N, Repp R, Römer W, Kalden JR, Helm G, Harrer T, Lorenz HM, Janka R.

AJR Am J Roentgenol. 2005 Sep;185(3):668-70. No abstract available.

PMID:
16120915
39.

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH.

Br J Haematol. 2005 Jul;130(2):218-28.

PMID:
16029450
40.

An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia.

Germeshausen M, Schulze H, Kratz C, Wilkens L, Repp R, Shannon K, Welte K, Ballmaier M.

Leukemia. 2005 Apr;19(4):611-7.

PMID:
15729385
41.

NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms.

Kracht T, Schrappe M, Strehl S, Reiter A, Elsner HA, Trka J, Cario G, Viehmann S, Harbott J, Borkhardt A, Metzler M, Langer T, Repp R, Marschalek R, Welte K, Haas OA, Stanulla M.

Haematologica. 2004 Dec;89(12):1492-7.

42.

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.

Brugger W, Hirsch J, Grünebach F, Repp R, Brossart P, Vogel W, Kopp HG, Manz MG, Bitzer M, Schlimok G, Kaufmann M, Ganser A, Fehnle K, Gramatzki M, Kanz L.

Ann Oncol. 2004 Nov;15(11):1691-8.

PMID:
15520073
43.

Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia.

Metzler M, Strissel PL, Strick R, Niemeyer C, Roettgers S, Borkhardt A, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Reinhardt D, Creutzig U, Beck JD, Rascher W, Repp R, Langer T.

Genes Chromosomes Cancer. 2004 Nov;41(3):291-6.

PMID:
15334554
44.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.

Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29.

45.

Efficient gene delivery with serum into human cancer cells using targeted anionic liposomes.

Mady MM, Ghannam MM, Khalil WA, Repp R, Markus M, Rascher W, Müller R, Fahr A.

J Drug Target. 2004 Jan;12(1):11-8.

PMID:
15203907
46.
47.

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A.

Blood. 2004 Apr 15;103(8):2920-4. Epub 2003 Dec 30.

48.

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.

Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ, Repp R, Valerius T, Fey GH.

Br J Haematol. 2004 Apr;125(2):167-79.

PMID:
15059139
49.

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M.

Br J Cancer. 2003 Dec 15;89(12):2234-43.

50.

A multiplex-PCR to identify hepatitis B virus--enotypes A-F.

Kirschberg O, Schüttler C, Repp R, Schaefer S.

J Clin Virol. 2004 Jan;29(1):39-43.

PMID:
14675868

Supplemental Content

Support Center